Drugs for Restless Legs Syndrome 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 9)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Rotigotine |
Approved |
Phase 4,Phase 3 |
|
99755-59-6, 92206-54-7 |
57537
|
Synonyms:
(6S)-6-(propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol
2-(N-N-Propyl-N-2-thienylethylamino)-5-hydroxytetralin
N 0437, (-)-Isomer
N 0437, (+-)-Isomer
N 0437, (R)-Isomer
|
N 0437, Hydrochloride, (R)-isomer
N 0437, Hydrochloride, (S)-isomer
Neupro
Rotigotine CDS
|
|
2 |
|
Dopamine |
Approved |
Phase 4,Phase 3 |
|
51-61-6, 62-31-7 |
681
|
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
3 |
|
Pramipexole |
Approved, Investigational |
Phase 4 |
|
104632-26-0 |
119570
59868
|
Synonyms:
(-)-Pramipexole
(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole
(S)-Nāā6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
104632-26-0
111GE001
2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole
2-amino-4,5,6,7-tetrahydro-6-Propylaminobenzothiazole
2-amino-6-propylaminotetrahydrobenzothiazole
2-amino-6-Propylaminotetrahydrobenzothiazole
4,5,6,7-tetrahydro-N6-Propyl-2,6-benzothiazole-diamine
6,7-tetrahydro-N6-Propyl-2,6-benzothiazolediamine dihydrochloride monohydrate
AC1L3P1T
BIDD:GT0250
C10H17N3S
CHEBI:8356
CHEMBL301265
CID119570
CPD000449298
D05575
Dexpramipexole
DivK1c_006916
Furfuryl Acetate
HMS2051A21
HMS2090C15
KBio1_001860
KBio2_002340
KBio2_004908
KBio2_007476
KBioSS_002343
LS-40722
|
Mirapex
MLS000758250
MLS001423952
MolPort-003-849-957
NCGC00167441-01
Pramipexol
Pramipexol [Spanish]
Pramipexol dihydrobromide, (+-)-isomer
Pramipexol dihydrochloride, (S)-isomer
Pramipexol, (+-)-isomer
Pramipexol, (R)-isomer
pramipexole
Pramipexole
Pramipexole (USAN/INN)
Pramipexole [USAN:INN]
Pramipexole 2HCl Monohydrate
Pramipexole hydrochloride
Pramipexolum
Pramipexolum [Latin]
SAM001247006
SBB070477
Sifrole
SMR000449298
SND 919CL2X
SND-919
SND919CL2X
SND-919CL2X
SpecPlus_000820
Spectrum_001838
Spectrum5_001453
SUD919CL2Y
U-98528E
|
|
4 |
|
Dopamine Agents |
|
Phase 4,Phase 3 |
|
|
|
5 |
|
Dopamine agonists |
|
Phase 4,Phase 3 |
|
|
|
6 |
|
Neurotransmitter Agents |
|
Phase 4,Phase 3 |
|
|
|
7 |
|
Antioxidants |
|
Phase 4 |
|
|
|
8 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
9 |
|
Protective Agents |
|
Phase 4 |
|
|
|
Interventional clinical trials:
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome |
Completed |
NCT01455012
|
Phase 4 |
Rotigotine;Placebo |
2 |
Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS) |
Completed |
NCT00472199
|
Phase 4 |
Pramipexole;Placebo |
3 |
DIalysis Symptom COntrol-Restless Legs Syndrome Trial |
Not yet recruiting |
NCT03806530
|
Phase 3 |
Gabapentin;Ropinirole;Placebo Gabapentin;Placebo Ropinirole |
4 |
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS) |
Completed |
NCT01569464
|
Phase 3 |
Rotigotine |
5 |
Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restless Legs Syndrome (RLS) |
Completed |
NCT00887289
|
|
|
|